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The pineal hormone melatonin (MLT) is a derivative of the amino acid 
L-tryptophan and controls the circadian diurnal rhythm and the seasonal bio-
rhythm. Exogenous administration is aimed at alleviating sleep-related dysfunc-
tions and jet lag, as it decreases sleep-onset latency, increases total sleep time and 
improves overall sleep quality. Besides these indications, MLT has been shown to 
have other actions, such as antioxidant, immune enhancement and anticancer. It 
has also been shown to be useful against cardiovascular, neurological and psychi-
atric diseases. In the context of this work, a review of the related literature on the 
modified release of MLT from its per os administered formulations is presented, 
including the utilization of the design of experiments (DoE) for the selection of 
the optimal composition of melatonin formulations. The chapter offers an account 
of the recent advantages on MLT’s solid dosage forms suitable for treating sleep 
disorders, referring either to its onset or maintenance.
Keywords: melatonin, circadian rhythm, sleep disorders, modified release, oral solid 
dosage forms, per os administration, experimental design
1. Introduction
Melatonin (MLT) is an indole amide hormone produced by the pineal gland, 
especially at night time and is mainly involved in the regulation of circadian and 
circannual rhythms. For clinical purposes (including Alzheimer’s disease, insomnia, 
stroke, depression, Parkinson’s disease, migraine, headache, etc.), exogenous MLT 
could be administered for alleviation of the symptoms. Irrespective of the pathologi-
cal case, MLT’s exogenous administration should mimic the typical nocturnal endog-
enous MLT levels. The release profile of these drug delivery systems should be in a 
controlled manner, due to MLT’s short half-life of elimination and low bioavailability.
Melatonin
2
The development of novel pharmaceutical formulations with the optimal release 
profile is of great importance for cases like melatonin. To this purpose, a series of 
experiments should be performed, utilizing various excipients at different ratios. 
These trials could require plenty of working hours, with no guarantee that, indeed, 
the optimal formulation composition will be reached. Therefore, the employment 
of a statistical/chemometric approach, such as design of experiments (DoE), can be 
beneficial for complicated and demanding tasks like the development of modified-
release formulations with a minimum number of experiments.
2.  Advances on the melatonin per os administered modified-release solid 
formulations
Scientific research has been conducted for the purpose of MLT evaluation not 
only towards medicine and clinical evaluation but also towards pharmaceutics [1–3]. 
Many researchers have studied and managed to produce immediate-release formula-
tions of MLT (tablets, creams, sublingual sprays, nasal preparations, injectables, 
etc.), in order to facilitate sleep-onset problems. MLT modified-release formulations 
are clinically more useful in initiating and maintaining sleep in elderly insomniacs 
than those designed for immediate release. More in particular, the sustained-release 
dosage form which delivers MLT in a time period over 8 h is of clinical value for 
those who have disordered circadian rhythms [4, 5]. Therefore, the modified release 
of MLT from oral solid dosage forms that alter the time and/or the rate of MLT 
release may provide an alternative for MLT delivery and be useful in the treatment 
of circadian rhythmic disorders, like insomnia, jet lag, seasonal affective disease, 
shift work syndrome, etc. [6]. The recent advantages of MLT modified-release per 
oral solid formulations are reviewed below and summarized in Table 1.
Aiming at this mode of release of MLT, a series of hydrophilic matrix tablets has 
been prepared and tested in vitro. The tablets comprised of combinations of excipi-
ents (hydroxypropyl methylcellulose K 15 M (HPMC), low-viscosity sodium algi-
nate, Avicel PH 102, etc.) and a variety of cyclodextrins (MLT (guest)-cyclodextrin 
(host) complexes in 1:1 ratio). The release studies that were performed in two disso-
lution media (acidic pH 1.2 and basic pH 7.4) suggested that melatonin was released 
faster from the MLT-cyclodextrin complexes than from the matrix systems possibly 
due to their increased solubility [7]. In another investigation, a rather unexploited 
biomaterial for applications in the design of drug delivery systems, the algal sul-
phated polysaccharide ulvan was used as an excipient in MLT solid dosage forms. The 
dissolution tests showed that the MLT release from the ulvan-based tablets followed 
a sigmoidal pattern, which denoted that the drug release is controlled by polymer 
relaxation and/or erosion [8]. In a similar study, hydrophilic matrix tablets with 
various excipients (hydroxypropyl methylcellulose K15 M, low-viscosity sodium 
alginate, lactose monohydrate and polyvinylpyrrolidone M.W.: 10.000 and 55.000) 
were developed and tested in vitro at two dissolution media (pH 1.2 and 7.4) in order 
to examine the modified-release characteristics of MLT. The objective was to produce 
a formulation with a quick initial pace, aiming at a satisfactory sleep onset, followed 
by a prolonged release that could target poor sleep quality problems. The dissolution 
results indicated that the combination of the excipients with different physicochemi-
cal properties could alter the release of MLT from solid matrix systems [9].
Moreover, researchers have developed matrix tablets comprised of common hydro-
gels (hydroxypropyl methylcellulose and dextran) to study the influence on the release 
profile of MLT in vitro and liposomes (of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
and dipalmitoylphosphatidylglycerol) incorporating the hormone in order to compare 




Delivery system Excipient (s) Reference
Modified Matrix tablets HPMC K15 M, MCC, sodium 
alginate and various cyclodextrins
[7]
Ulvan, HPMC K15 M, low-viscosity 
sodium alginate, LM, PVP
[8]
PVP (M.W.: 10.000 and 55.000), 
sodium alginate (low viscosity 2%), 
HPMC K15 M, dextran, MCC, LM
[9]
Dextran, MCC, HPMC K15 M, 
MCC, LM
[10],
Liposomes DPPC, DPPG [10]
Nanofibrous electrospun 
mats incorporated into 
monolayered and three-
layered tablets
PVP (M.W.: 1.300.000), CA (M.W.: 
50.000), HPMC K15 M, LM
[11]
Electrospun nanofibres in 
capsules
PVP (M.W.: 1.300.000), CA (M.W.: 
50.000), hypromellose 2910, PEO 
(M.W. 900.000 and 400.000)
[12]
Calcium alginate beads in 
hard gelatin capsules
[13]
Slow Matrix tablets HPMC, Carbopol 971P, MCC, 
maize starch
[14]
Sustained Matrix tablets HPMC, Avicel, Primojel, Ac-Di-Sol, 
Polyplasdone, Mg stearate, Talc, 
Cab-O-Sil
[15]
Solid lipid nanoparticles in 
hard gelatin capsules
Stearic acid, Epikuron 200, lactose [16]
Controlled Matrix tablets HPMCK15 M, low-viscosity
sodium alginate, LM, PVP (M.W.: 
10.000 or 55.000)
[17]
Beads Sodium alginate, Eudragit® RS100, 
aluminum tristearate, polyethylene, 
glycol 400, liquid paraffin
[18]
Delayed Compression-coated tablets Dextran, PVP(M.W.: 10.000), ethyl 
cellulose (45cps), Avicel PH 102, 
LM, sodium alginate
[19]
Biphasic Matrix tablets Dextran, PVP (10.000), ethyl 





Bilayer tablets Dextran, ethyl cellulose (45cps), 
MCC, LM, sodium alginate
[19]





Coated beads in hard gelatin 
capsule
Core sugar spheres, Aquacoat®, 
dibutyl sebacate, triethyl citrate, 
PVP, HPMC
[20]
HPMC: Hydroxypropyl methylcellulose, MCC: Microcrystalline cellulose (avicel PH 102), PVP: Polyvinylpyrrolidone, PEO: 
Polyethylene oxide, CA: Cellulose acetate, LM: Lactose monohydrate, DPPC: 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 
DPPG: Dipalmitoyl-phosphatidylglycerol.
Table 1. 
An overview of the recent advantages of MLT modified-release per oral solid formulations.
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their release profiles. The results indicated that both formulations (liposomal and solid 
matrix tablets) could be suitable alternatives for treating sleep-onset/maintenance 
problems [10].
Once more, aiming at the modified release of MLT, another group of researchers 
studied the MLT release from monolayered and three-layered tablets, incorporat-
ing nanofibrous mats composed of cellulose acetate and polyvinylpyrrolidone. The 
in vitro dissolution release studies of the MLT formulations in simulated gastroin-
testinal fluids revealed tableting pressure and pH dependence. Comparing the MLT 
release from the physical mixture tablets and from the nanofibre-based tablets, it 
was concluded that the release profile was generally slower than the latter, render-
ing the formulation suitable for both sleep-onset and maintenance dysfunctions 
[11]. The same group of researchers produced electrospun-MLT loaded nanofibres 
(with cellulose acetate, polyvinylpyrrolidone and hydroxypropyl methylcellulose, 
as excipients) and used them to fill hard gelatin and delayed-release (DRcaps™) 
capsules. The in vitro dissolution results revealed a modified-release profile of MLT 
from the fabricated matrices in gastrointestinal-like fluids and suggested that the 
MLT-loaded nanofibrous mats could exhibit a promising profile for treating sleep 
problems [12].
Calcium alginate beads were also prepared to investigate the MLT modified 
release. Excipients utilized in their preparation included calcium alginate, polyvi-
nylpyrrolidone (M.W.: 10.000 and 55.000), hydroxypropyl methylcellulose (M.W.: 
15.000 and 100.000), lactose monohydrate and, as a surfactant, sodium lauryl 
sulphate. The in vitro release of melatonin was investigated at two different pHs 
(acidic pH 1.2 and basic pH 6.8), and the results concluded that the hormone’s 
release from the beads was reversibly proportional to the extent of their expansion, 
which depends on the molecular weight/viscosity of the biopolymers present in the 
beads; the higher the molecular weight/viscosity of the hydrogels, the greater the 
beads swelling and the less the MLT’s release [13].
Another group of researchers prepared a slow-release tablet of MLT with vary-
ing quantities of hydroxypropyl methylcellulose K15 M and Carbopol 971P, as well 
as other excipients (microcrystalline cellulose, maize starch, magnesium stearate 
and purified talc). The formulations developed showed a slow release of MLT dur-
ing an 8 h period [14].
To the same end, matrix tablets were formulated using hydroxypropyl meth-
ylcellulose and tested in vitro in relation to drug release, as a function of polymer 
viscosity, drug loading, type and amount of disintegrant, lubricant and glidant 
and aqueous polymeric coating level, and further compared with two commercial 
products. The release studies showed that as the polymer viscosity increased, the 
release decreased, and as the coating level increased, an increased lag time was 
observed [15]. Other researchers have examined the in vivo sustained release of 
MLT that was incorporated in solid lipid nanoparticles. The results indicated that 
solid lipid nanoparticles may act as a reservoir, permitting a constant and prolonged 
MLT release, after oral administration, which may indicate new possibilities for 
sustained delivery systems [16].
In another research project, controlled-release matrix tablets of MLT were 
developed by the use of a computer programme, D-optimal experimental design, 
aiming at affecting its modified release at simulated gastrointestinal media. The 
careful selection of the excipients (polyvinylpyrrolidone (M.W.: 10.000 and 
55.000), hydroxypropyl methylcellulose K15 M and lactose monohydrate) at their 
appropriate quantity resulted to the optimal solution and the controlled release of 
melatonin with the minimal number of experiments [17]. Moreover, in another 
research, polymer-reinforced and polymer-coated alginate beads with various con-
centrations of polymer (Eudragit® RSI00) and plasticizer (aluminum tristearate) 
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were produced and evaluated in vitro in relation to their controlled-release char-
acteristics as an alternative for oral delivery of MLT. The results indicated that the 
polymeric reinforcement offered an initial burst release in intestinal fluids, while 
the coating led to release retardation in both gastric and intestinal fluids. The results 
also showed that as the polymer concentration increased, the MLT release decreased 
in the intestinal fluids, due to coated alginate beads disintegration [18].
Researchers have also probed the MLT release from matrix and compression-
coated tablets that were comprised of combinations of ethyl cellulose, polyvinyl-
pyrrolidone, dextran, low-viscosity sodium alginate, Avicel PH 102 and lactose 
monohydrate. The results obtained revealed that the initial release of melatonin 
was more delayed from coated tablets than from the respective uncoated. The 
matrix tablets showed an initial fast release that followed a sustained mode, dem-
onstrating that the use of various excipients results to different controlled-release 
behaviors [19].
Also, bilayered tablets incorporating an immediate-release layer and a sustained-
release layer were developed by the same group of researchers using as excipients 
ethyl cellulose, dextran, low-viscosity sodium alginate, Avicel PH 102, lactose 
monohydrate, iron oxide pigment red 30 and magnesium stearate. The dissolu-
tion results revealed immediate and sustained drug release [19]. Another group of 
researchers also prepared bilayered tablets of MLT incorporating an immediate-
release part consisting of MLT-b-cyclodextrin inclusion complex and a sustained-
release part containing MLT in hydroxypropyl methylcellulose K15 M and Carbopol 
971P. The results showed an initial burst followed by a near zero-order release 
pattern for a period of 8 h [20].
Furthermore, scientists have designed an MLT oral formulation to provide 
immediate and controlled release, which consisted of MLT-loaded sugar beads 
coated with 20% Aquacoat®. The in vivo results showed average peak plasma 
concentration at about 600 pg/ml that maintained at approximately 100 pg/ml over 
8 h, indicating biphasic release [20].
Researchers have also utilized principles of nanotechnology to make micro−/
nanoparticles containing MLT that could be further formulated to solid per os mod-
ified-release formulations. Thus, MLT was loaded in poly(D,L-lactide-co-glycolide) 
nanoparticles and microparticles (diameter of 200 nm and 3.5 mm, respectively). 
The cumulative release curves for nano- and microparticles revealed that for PLGA 
nano-10 and PLGA nano-20, approximately 30 and 20% of melatonin were released, 
respectively, within the first 24 h, as due to the diffusion of melatonin molecules 
located closer to the particle surface. At the end of 40 days, approximately 65% of 
the loaded melatonin was released from PLGA nanoparticles by diffusion mecha-
nism [21]. Similarly, MLT was encapsulated into poly(lactic-co-glycolic acid) micro-
spheres, and the release results indicated a dual pattern: a low initial burst release 
(around 40%) after the first 3 days and a relatively prolonged release over 25 days 
(around 85% of total MLT release) [22]. Furthermore, scientists have prepared MLT 
nanocapsules with Eudragit® S100. This formulation revealed a modified-release 
profile, which when fitted to a monoexponential model revealed that the MLT release 
mechanism was controlled by swelling and dissolution of the polymer [23].
3.  Employment of DoE for the development of novel MLT  
modified-release formulations
In the vast majority of experimental procedures in all scientific fields, the 
optimal conditions are reached by modifying the levels of one factor at a time 
(OFAT) while keeping all the rest that seem to affect the response constant. 
Melatonin
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This classical strategy usually requires a large number of experimental runs 
and subsequent working hours. However, it ignores any potential interactions 
among the factors, and this is a major drawback, as it may result in an eventually 
ineffective procedure. On the contrary, a more organized way of conducting 
experiments, based on statistics, could be cost-effective and time-saving and 
also enable reaching the real optimal conditions. There are various chemometric 
approaches, but the most suitable for optimization of a procedure is the design of 
experiments.
DoE has been applied in many fields, including pharmaceutical product 
development [24–28]. It is gaining an increasing interest among pharmaceutical 
researchers, as more and more are becoming familiar with this approach, due to the 
relatively recent requirement for quality-by-design (QbD) principles. Furthermore, 
DoE has proven its usefulness in a variety of pharmaceutical applications in this 
field. Its major advantage has to do with obtaining the optimal conditions among 
factors for the desired values of responses by conducting a small number of experi-
ments. That way DoE can resolve problems in complex systems, which cannot be 
easily managed by the trial-and-error approach.
Among the various types of designs like (fractional) factorial, Box–Behnken, 
central composite design (CCD), etc., the D-optimal design has been established as 
a robust design strategy. It enables the assessment of both numerical and categori-
cal factors [29], and regarding numerical factors, the latter are examined at many 
different levels (design matrix), and not at 3–5, as the more classical designs. These 
levels are generated automatically by computer algorithms from relevant softwares, 
in order to satisfy the D-optimality criterion, aiming to minimize the general-
ized variance of the estimated regression coefficients without increasing the total 
number of experimental runs.
Such design was employed in the study presented by Vlachou et al. [17] regard-
ing MLT controlled-release matrix formulations. One categorical factor, namely, the 
M.W. of polyvinylpyrrolidone (PVP), was chosen (M.W.: 10.000, low, and 55.000, 
high), and two numerical factors, namely, the mass (mg) of PVP and hydroxypro-
pyl methylcellulose K15 M, were selected. When a modified release is the aim, as in 
the current study, setting the right responses is very critical. Herein, the need for a 
fully release melatonin in a controlled manner within 8 h was the reason for set-
ting as responses the time for 50% drug dissolution at pH = 1.2 and the diffusional 
exponent (n) at pH values 1.2 and 7.4. Initially, a quick melatonin’s release is needed 
for treating sleep-onset problems, while its subsequent slow release is needed to 
improve sleep quality and/or to assist maintain sleep. Therefore, T50% (pH: 1.2) 
should be ≤150 min, so that an initial dose will be released to aid the sleep onset of 
patients, and n (pH: 1.2) = 0.89, in order to achieve zero-order release kinetics and 
Case II diffusion, and n (pH: 7.4) = 0.80 for first-order release kinetics and anoma-
lous diffusion.
The experiments were conducted as suggested by the experimental plan of 
Design-Expert software, and then suitable quadratic models were obtained for all 
(3) responses, satisfying all statistical criteria (ANOVA test, lack-of-fit test, R2, adj. 
R2 and pred. R2 values). The next step was to estimate the overall optimal condi-
tions, and thus Derringer’s desirability function was employed [30], taking into 
account the necessity for simultaneous optimization of the aforementioned objec-
tives/responses. Desirability function is a tool that is usually included in experi-
mental design softwares and therefore very useful for projects in pharmaceutical 
development. Each predicted response Ŷi and experimentally obtained response Yi 
can be transformed to a desirability function di. The latter can have a value from 0 
to 1, where di = 0 represents completely undesirable response and di = 1 represents 
completely desirable or ideal response. The individual desirability scores di can then 
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be combined on a single overall (global) desirability D, which is optimized to find 
the optimum set of input variables:
  D =  ( d 1 ×  d 2 × … ×  d n ) 
 1 _ n (1)
with n denoting the number of responses.
In order to reach to optimal solution, the importance of responses should be 
set by adjusting the importance coefficients. T50% (pH, 1.2) was set as the most 
important response for consideration, while the rest two were of equal importance. 
Furthermore, weights (which denote the desired trend of the response within 
itself) and the range of responses could be changed, according to defined objec-
tives. The optimal solution was reached with a value of global desirability of 0.907, 
which can be considered as very satisfactory. The suggested solution was per-
formed, and the obtained results were in agreement with the goals defined for the 
responses and the predictions of the software. Consequently, with just 17 experi-
ments defined by Design-Expert software and few preliminary in order to set the 
limits of the factors for the experimental plan, a novel MLT modified-release oral 
solid dosage form was developed.
To the best of our knowledge, the previous study was the only attempt to 
develop novel and improved MLT formulations by utilizing DoE. There has been a 
previous study [31] in which a different chemometric tool, artificial neural net-
works (ANN), was utilized. In that study, researchers prepared 27 different tablet 
formulations with different amounts of hydroxypropyl methylcellulose, xanthan 
gum and Carbopol® 974P NF. These formulations were subjected to drug release 
studies, using dissolution test data as inputs for ANN. The authors suggest that 
ANN with nine neurons in the hidden layer had the best results, meaning that it 
could predict, after training, dissolution data. In other words, this was a completely 
different strategy, based on training of the network and prediction of response 
values for novel (but not very different from training data) excipient mixtures. The 
optimal solution may not be reached, as the new mixtures are suggested by the user 
(trial and error) and then tested by the software. On the contrary, DoE is a tool for 
optimization of a procedure and not prediction of response values, and therefore it 
is recommended for application in such projects.
4. Conclusions
This analysis aims at the review of the latest advances of MLT modified-release 
oral solid dosage forms including the design of experiments approach. Many sci-
entists have focused on the different ways in manufacturing modified-release oral 
solid formulations by using various excipients, dosage forms (multilayer or bilayer, 
coated or uncoated tablets), liposomes, alginate beads, nanofibre mats and nano−/
microparticles, or by employing a variety of techniques (i.e. dry coating, electros-
pinning, experimental design, etc.) in order to gain knowledge for the production 
of such dosage forms.
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